PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: Sweden

PE Guidelines
General guidelines for economic evaluations from The Dental and Pharmaceutical Benefits Agency (2003)
PDF in English
PDF in Swedish

PE Guidelines Source:
The Dental and Pharmaceutical Benefits Agency (TLV)
www.tlv.se

Additional Information:
Evaluation and Synthesis of Studies Using Qualitative Methods of Analysis. Handbook, The Swedish Council on Health Technology Assessment. February, 2013.
www.sbu.se/handbook (English version, first part of SBVís handbook)
http://www.sbu.se/upload/ebm/metodbok/SBUsHandbok.pdf (Swedish version, SBVís Handbook)

The Swedish Council on Health Technology Assessment (SBU)
www.sbu.se

Last Webpage Update: Monday, June 20, 2016

PE Guidelines Key Features:

Key Features:  
Title and year of the documentGeneral guidelines for economic evaluations from the Pharmaceutical Benefits Board (2003) 
Affiliation of authorsPharmaceutical Benefits Board 
Purpose of the documentA list of criteria to be met for recognition of medical technologies/services as reimbursable 
Standard reporting format includedNo 
DisclosureYes 
Target audience of funding/ author's interestsPharmaceutical companies. Pharmaceutical Benefit Board 
PerspectiveSocietal 
IndicationYes 
Target populationYes 
Subgroup analysisYes, gender, age, severity, risk level 
Choice of comparatorMost used 
Time horizonShall cover the period when the main health effects and costs arise. 
Assumptions requiredNot stated 
Preferred analytical techniqueCEA, CUA 
Costs to be includedAll relevant costs. Production loss estimated by human capital approach 
Source of costsApoteketís Sales Price for drugs 
ModelingYes, requires details 
Systematic review of evidencesNot stated 
Preference for effectiveness over efficacyNot stated 
Preferred outcome measureQALY. If CBA- WTP 
Preferred method to derive utilityStandard gamble, time trade-off, EQ-5D. Prefer weights from ill-person. 
Equity issues statedNot stated 
Discounting costsBase:3%; SA:0~5%; 3% 
Discounting outcomesBase:3%; SA:0~5%; 0% 
Sensitivity analysis-parameters and rangeAt central assumptions and parameters 
Sensitivity analysis-methodsNot specific 
Presenting resultsMethods, assumptions made and detailed data shall be shown clearly that the different steps in the analysis are easily followed. 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Not specific 
Portability of results (Generalizability)Yes, under modeling analysis 
Financial impact analysisNo 
Mandatory or recommended or voluntary 

Acknowledgement: Mr. Lars Bernfort provided the updated information ( Mr. Lars Bernford, Center for Medical Technology Assessment (CMT), Division of Health Care Analysis (HSA), Department of Medical and Health Sciences (IMH), LinkŲping University)

Country Selection Page | PE Guidelines Index Page